UbiVac is a clinical stage immuno-oncology company that specializes in groundbreaking immunotherapies for cancer and infectious diseases. With a strong focus on research, development, and testing, UbiVac has been at the forefront of therapeutic immunotherapy strategies since 2005. Their lead product, DPV-001 (DRibble), is an innovative immune activator and vaccine/combination immunotherapy.

This off-the-shelf treatment is currently in a National Cancer Institute-supported Phase II clinical trial for the adjuvant treatment of non-small cell lung cancer (NSCLC). Promisingly, results from this trial have shown that DPV-001 induces and/or enhances the immune response in every patient who received the treatment. UbiVac's pipeline of technologies and vaccines aims to empower the immune system to recognize and attack cancer cells more effectively.

By inducing or boosting immunity against a wide range of cancer targets, UbiVac's patented technology complements existing drug portfolios in the pharmaceutical and biotechnology industry. Furthermore, UbiVac's DRibble technology enables multiple mechanisms of immune-mediated destruction of cancer cells, including the activation of B cells, T cells, and innate immune cells like NK cells. These approaches have shown great promise in preclinical studies and are now being tested in combination immunotherapy trials for advanced head and neck cancer.

In addition to their focus on immunotherapies, UbiVac is also preparing to launch cell-based therapies, leveraging their extensive experience in Adoptive Cellular Immunotherapy. They believe that their cell-based therapies combined with their immune activating and vaccine technology will help improve outcomes for patients with cancer. Overall, UbiVac is a pioneering brand that is pushing the boundaries of immuno-oncology and offering innovative solutions to combat cancer and infectious diseases